Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein

Journal of Pathology

Volumn 229, Issue 5, 2013, Pages 743-754

  Kobos, Rachel ^a   Nagai, Makoto ^a   Tsuda, Masumi ^a   Merl, Man Yee ^a,e   Saito, Tsuyoshi ^a,b   Laé, Marick ^a,d   Mo, Qianxing ^a,c   Olshen, Adam ^a,f   Lianoglou, Steven ^a   Leslie, Christina ^a   Ostrovnaya, Irina ^a   Antczak, Christophe ^a   Djaballah, Hakim ^a   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JUNTENDO UNIVERSITY   (Japan)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d INSTITUT CURIE   (France)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

alveolar soft part sarcoma; ASPSCR1; chromosomal translocation; CYP17A1; NAMPT; renal carcinoma; TFE3; uridine phosphorylase

Indexed keywords

ASPSCR1 PROTEIN; ONCOPROTEIN; RNA; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E3; UNCLASSIFIED DRUG;

ALVEOLAR SOFT PART SARCOMA; ARTICLE; CANCER CELL; CANCER GENETICS; CARCINOGENESIS; CELL PROLIFERATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RNA ANALYSIS; UPREGULATION;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CHROMATIN IMMUNOPRECIPITATION; CLUSTER ANALYSIS; COS CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; GENES, REPORTER; GENOMICS; GENOTYPE; HEK293 CELLS; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MCF-7 CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; SARCOMA, ALVEOLAR SOFT PART; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 84875054627     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4158     Document Type: Article

References (51)

1. Ladanyi M, Lui MY, Antonescu CR, et al,. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001; 20: 48-57.
2. Argani P, Antonescu CR, Illei PB, et al,. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001; 159: 179-192.
3. Kayton ML, Meyers P, Wexler LH, et al,. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg 2006; 41: 187-193.
4. Argani P, Olgac S, Tickoo SK, et al,. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007; 31: 1149-1160.
5. Ishiguro M, Iwasaki H, Ohjimi Y, et al,. Establishment and characterization of a renal cell carcinoma cell line (FU-UR-1) with the reciprocal ASPL-TFE3 fusion transcript. Oncol Rep 2004; 11: 1169-1175.
6. Hemesath TJ, Steingrimsson E, McGill G, et al,. microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 1994; 8: 2770-2780.
7. Rehli M, Den Elzen N, Cassady AI, et al,. Cloning and characterization of the murine genes for bHLH-ZIP transcription factors TFEC and TFEB reveal a common gene organization for all MiT subfamily members. Genomics 1999; 56: 111-120.
8. Zhao GQ, Zhao Q, Zhou X, et al,. TFEC, a basic helix-loop-helix protein, forms heterodimers with TFE3 and inhibits TFE3-dependent transcription activation. Mol Cell Biol 1993; 13: 4505-4512.
9. Beckmann H, Su LK, Kadesch T,. TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif. Genes Dev 1990; 4: 167-179.
10. Haq R, Fisher DE,. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 2011; 29: 3474-3482.
11. Yu C, Cresswell J, Loffler MG, et al,. The glucose transporter 4-regulating protein TUG is essential for highly insulin-responsive glucose uptake in 3 T3-L1 adipocytes. J Biol Chem 2007; 282: 7710-7722.
12. Bogan JS, Hendon N, McKee AE, et al,. Functional cloning of TUG as a regulator of GLUT4 glucose transporter trafficking. Nature 2003; 425: 727-733.
13. Rubin BR, Bogan JS,. Intracellular retention and insulin-stimulated mobilization of GLUT4 glucose transporters. Vitam Horm 2009; 80: 155-192.
14. Bogan JS, Kandror KV,. Biogenesis and regulation of insulin-responsive vesicles containing GLUT4. Curr Opin Cell Biol 2010; 22: 506-512.
15. Tsuda M, Davis IJ, Argani P, et al,. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007; 67: 919-929.
16. Weterman MJ, van Groningen JJ, Jansen A, et al,. Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins. Oncogene 2000; 19: 69-74.
17. Takebayashi K, Chida K, Tsukamoto I, et al,. The recessive phenotype displayed by a dominant negative microphthalmia-associated transcription factor mutant is a result of impaired nucleation potential. Mol Cell Biol 1996; 16: 1203-1211.
18. Taylor BS, Barretina J, Maki RG, et al,. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 2011; 11: 541-557.
19. Filion C, Motoi T, Olshen AB, et al,. The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J Pathol 2009; 217: 83-93.
20. Ho AL, Deraje Vasudeva S, Lae M, et al,. PDGF receptor-α is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res 2012; 72: 4515-4525.
21. Foat BC, Morozov AV, Bussemaker HJ,. Statistical mechanical modeling of genome-wide transcription factor occupancy data by MatrixREDUCE. Bioinformatics 2006; 22: e141-149.
22. Hasmann M, Schemainda I,. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003; 63: 7436-7442.
23. Thakur BK, Dittrich T, Chandra P, et al,. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. Biochem Biophys Res Commun 2012; 424: 371-377.
24. Bi TQ, Che XM, Liao XH, et al,. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol Rep 2011; 26: 1251-1257.
25. Travelli C, Drago V, Maldi E, et al,. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells. J Pharmacol Exp Ther 2011; 338: 829-840.
26. Wang B, Hasan MK, Alvarado E, et al,. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 2011; 30: 907-921.
27. Lazar AJ, Das P, Tuvin D, et al,. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007; 13: 7314-7321.
28. Stockwin LH, Vistica DT, Kenney S, et al,. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer 2009; 9: 22.
29. Kido S, Miyamoto K, Mizobuchi H, et al,. Identification of regulatory sequences and binding proteins in the type II sodium/phosphate cotransporter NPT2 gene responsive to dietary phosphate. J Biol Chem 1999; 274: 28256-28263.
30. Hua X, Miller ZA, Wu G, et al,. Specificity in transforming growth factor-β-induced transcription of the plasminogen activator inhibitor-1 gene: interactions of promoter DNA, transcription factor muE3, and Smad proteins. Proc Natl Acad Sci USA 1999; 96: 13130-13135.
31. Hua X, Miller ZA, Benchabane H, et al,. Synergism between transcription factors TFE3 and Smad3 in transforming growth factor-β-induced transcription of the Smad7 gene. J Biol Chem 2000; 275: 33205-33208.
32. Motyckova G, Weilbaecher KN, Horstmann M, et al,. Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci USA 2001; 98: 5798-5803.
33. Martignoni G, Gobbo S, Camparo P, et al,. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol 2011; 24: 1313-1319.
34. Wong SC, Moffat MA, Coker GT, et al,. The 3′ flanking region of the human tyrosine hydroxylase gene directs reporter gene expression in peripheral neuroendocrine tissues. J Neurochem 1995; 65: 23-31.
35. Verastegui C, Bertolotto C, Bille K, et al,. TFE3, a transcription factor homologous to microphthalmia, is a potential transcriptional activator of tyrosinase and TyrpI genes. Mol Endocrinol 2000; 14: 449-456.
36. Conley AJ, Bird IM,. The role of cytochrome P450 17 α-hydroxylase and 3β-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the δ5 and δ4 pathways of steroidogenesis in mammals. Biol Reprod 1997; 56: 789-799.
37. Payne AH,. Hormonal regulation of cytochrome P450 enzymes, cholesterol side-chain cleavage and 17α-hydroxylase/C17-20 lyase in Leydig cells. Biol Reprod 1990; 42: 399-404.
38. Voutilainen R, Tapanainen J, Chung BC, et al,. Hormonal regulation of P450scc (20,22-desmolase) and P450c17 (17α-hydroxylase/17,20-lyase) in cultured human granulosa cells. J Clin Endocrinol Metab 1986; 63: 202-207.
39. Chung BC, Picado-Leonard J, Haniu M, et al,. Cytochrome P450c17 (steroid 17α-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci USA 1987; 84: 407-411.
40. Locke JA, Fazli L, Adomat H, et al,. A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer. Prostate 2009; 69: 928-937.
41. Deneen B, Hamidi H, Denny CT,. Functional analysis of the EWS/ETS target gene uridine phosphorylase. Cancer Res 2003; 63: 4268-4274.
42. Im YS, Shin HK, Kim HR, et al,. Enhanced cytotoxicity of 5-FU by bFGF through up-regulation of uridine phosphorylase 1. Mol Cell 2009; 28: 119-124.
43. Adjei AA, Schwartz B, Garmey E,. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 2011; 16: 788-799.
44. Oike Y, Yasunaga K, Suda T,. Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. Int J Hematol 2004; 80: 21-28.
45. Aoi J, Endo M, Kadomatsu T, et al,. Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. Cancer Res 2011; 71: 7502-7512.
46. Revollo JR, Grimm AA, Imai S,. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279: 50754-50763.
47. Bi TQ, Che XM,. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 2010; 10: 119-125.
48. Nakajima TE, Yamada Y, Hamano T, et al,. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010; 101: 1286-1291.
49. Folgueira MA, Carraro DM, Brentani H, et al,. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005; 11: 7434-7443.
50. Shackelford RE, Bui MM, Coppola D, et al,. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol 2010; 3: 522-527.
51. von Heideman A, Berglund A, Larsson R, et al,. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol 2010; 65: 1165-1172.